Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q3 EPS by 14c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q3 EPS of $0.30, $0.14 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $102.7 million versus the consensus estimate of $113.66 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Worthington Enterprises raises dividend 5%, adds board member
• Morgan Stanley upgrades CDW on stronger AI-driven server demand